Diabetes drug semaglutide may fight inflammation and protect blood vessels
NCT ID NCT07314684
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 4 trial tests whether adding semaglutide to standard diabetes treatment reduces inflammation and improves blood vessel health in 80 people with type 2 diabetes who have no heart disease. Participants receive either semaglutide injections plus standard care or standard care alone for 52 weeks. Researchers will measure changes in inflammatory markers and blood vessel function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide (a GLP-1 receptor agonist drug)
What this could lead to
If successful, this could show that semaglutide helps control inflammation and blood vessel damage in type 2 diabetes, potentially reducing heart disease risk.
What could go wrong
This is a small, early-phase trial (80 people) looking at biomarkers, not clinical outcomes. The results may not translate to fewer heart attacks or strokes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliera Sant'Anna e San Sebastiano
RECRUITINGCaserta, Caserta, 81100, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Federico II University
RECRUITINGNaples, Napoli, 80131, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••